A Phase III, Double-blind, Placebo-controlled, Multi-center International Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Stages II and III Non-small Cell Lung Cancer (AEGEAN)
A Phase III, Double-blind, Placebo-controlled, Multi-center International Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Stages II and III Non-small Cell Lung Cancer (AEGEAN)
This is a Phase III, randomized, double-blind, placebo-controlled, multi-center international study assessing the activity of durvalumab and chemotherapy administered prior to surgery compared with placebo and chemotherapy administered prior to surgery in terms of pathological complete response.
Inclusion Criteria:
Exclusion Criteria:
CABA, C1012AAR, Argentina
CABA, C1280AEB, Argentina
Gyöngyös - Mátraháza, 3200, Hungary
Habikino-shi, 583-8588, Japan
Himeji-shi, 670-8520, Japan
Iwakuni-shi, 740-8510, Japan
Kitaadachi-gun, 362-0806, Japan
Kitakyushu-shi, 807-8555, Japan
Kurashiki Shi, 701 0192, Japan
Osakasayama-shi, 589-8511, Japan
Toyoake-shi, 470-1192, Japan